Conference Presentations

Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer. Abstract # 874P, ESMO 2017 Congress on Sunday, September 10, 2017. View PDF

Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX). Abstract # 744P, ESMO 2017 Congress on Saturday, September 9, 2017. View PDF

Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update. Abstract # 1316P, ESMO 2017 Congress on Saturday, September 9, 2017. View PDF

PEGylated human IL‐10 (AM0010) in combination with pembrolizumab in anti‐PD1 and CTLA‐4 refractory melanoma. Abstract #3084, ASCO 2017 Annual Meeting on June 5, 2017. View PDF

Efficacy and safety of PEGylated human IL‐10 (AM0010) in combination with an anti‐PD‐1 in renal cell cancer. Abstract #4567, ASCO 2017 Annual Meeting on June 4, 2017. View PDF

Efficacy, safety, and immune activation with PEGylated human IL‐10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC). Abstract #4111, ASCO 2017 Annual Meeting on June 3, 2017. View PDF

Efficacy, safety, and immune activation with PEGylated human IL‐10 (AM0010) in combination with an anti‐PD1 in advanced NSCLC. Abstract #9091, ASCO 2017 Annual Meeting on June 3, 2017. View PDF

PEGylated human IL‐10 (AM0010) monotherapy in refractory metastatic colorectal cancer. Abstract #3571, ASCO 2017 Annual Meeting on June 3, 2017. View PDF

Phase 1 Study with PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX - Immune Biomarker Update. Abstract #157, 2017 ASCO-SITC Clinical Immuno-Oncology Symposium on February 23-25, 2017. View PDF

Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). Abstract #399, 2017 ASCO Gastrointestinal Cancers Symposium on January 20, 2017. View PDF

Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1. Abstract #364PD, ESMO 2016 Congress on October 9, 2016. View PDF

Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1. Abstract #B010, CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference on September 26, 2016. View PDF

Clinical activity and safety of PEGylated human IL-10 (AM0010) in combination with anti-PD1. Abstract #3018, American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2016. View PDF

Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer. Abstract #3082, American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2016. View PDF

Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors. Abstract, AACR Annual Meeting on April 19, 2016. View PDF

PEGylated human IL-10 (AM0010) in advanced solid tumors. ESMO Symposium on Immuno-Oncology in Lausanne, Switzerland on November 20 - 21, 2015. View PDF

Phase 1 with PEGylated Recombinant Human IL-10 (AM0010) in Patients with Advanced Solid Tumors. Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs in National Harbor, Maryland on November 7, 2015. View PDF

PEGylated IL-10 (AM0010) for advanced solid tumors - a Phase 1 study. Abstract A194, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA on November 6, 2015. View PDF

PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a Phase 1 study. Abstract A028, CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, Translating Science into Survival 2015. View PDF

A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Abstract #3017, Annual Meeting of the American Society of Clinical Oncology, May 30, 2015. View PDF

A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. Abstract #TPS3126, 50th Annual Meeting of the American Society of Clinical Oncology, June 1, 2014. View PDF